title: Ranibizumab for exudative age-related macular degeneration in eyes previously treated with alternative vascular endothelial growth factor inhibitors.
authors.affiliation: Wills Eye Institute, Philadelphia, Pennsylvania, USA.
authors.forename: Justis P
authors.initials: JP
authors.lastname: Ehlers
authors.forename: Marc J
authors.initials: MJ
authors.lastname: Spirn
authors.forename: Chirag P
authors.initials: CP
authors.lastname: Shah
authors.forename: Gregory L
authors.initials: GL
authors.lastname: Fenton
authors.forename: Paul S
authors.initials: PS
authors.lastname: Baker
authors.forename: Carl D
authors.initials: CD
authors.lastname: Regillo
authors.forename: Allen C
authors.initials: AC
authors.lastname: Ho
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide / Q000008:administration & dosage; D000068258:Bevacizumab; D005122:Exudates and Transudates; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005654:Fundus Oculi; D006801:Humans; D007267:Injections; D008266:Macula Lutea / Q000473:pathology*; D008268:Macular Degeneration / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D000069579:Ranibizumab; D012189:Retrospective Studies; D013997:Time Factors; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014792:Visual Acuity; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide; D042461:Vascular Endothelial Growth Factor A; C495058:pegaptanib; D000068258:Bevacizumab; D000069579:Ranibizumab